Myasthenia Gravis Clinical Trial
Official title:
Prospective Observational Trial to Evaluate Clinical Prognosis and the Risk Factors for Progression for Myasthenia Gravis Patients
This study collects the clinical data of myasthenia gravis (MG) patients, assesses outcomes and adverse effects of different treatment regimens, and searches for risk factors of conversion to generalized MG.
Status | Recruiting |
Enrollment | 2000 |
Est. completion date | December 31, 2024 |
Est. primary completion date | June 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years and older |
Eligibility | Inclusion Criteria: 1. Age >14. 2. Clinical Diagnosis of MG with supporting evidence: 1. unequivocal clinical response to pyridostigmine 2. positive antibody testing 3. decrement >10% in repetitive nerve stimulations study (RNS) . 3. Willingness to sample collection, imaging study and other disease-related examinations and assessments. 4. Patients with informed consent. Exclusion Criteria: 1. History of chronic degenerative, psychiatric, or neurologic disorder other than MG that can produce weakness or fatigue. 2. Age =14 years. 3. Severe anxiety, depression or schizophrenia. 4. Cognitive impairment or mini-mental state examination (MMSE) score =24. 5. Severe systemic illness with life-expectancy less than 4 years. 6. Unwillingness to consent for collection of biological samples. 7. Inability to provide informed consent. |
Country | Name | City | State |
---|---|---|---|
China | Xuan Wu Hospital, Capital Medical University | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Da, Yuwei, M.D. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Conversion rates from ocular to generalized MG at the last visit and risk factors. | Ocular MG patients are followed up to determine the ratio of conversion to generalized disease at the end of follow-up. The clinical records will be retrospectively analyzed to search for risk factors of progressing. | Baseline, 48 months | |
Primary | Change in Quantitative Myasthenia Gravis (QMG) Scores from Baseline to 48 months. | The QMG is a 13-item scale which measures ocular, bulbar, limb function and respiratory function. The total score ranges from 0 (no myasthenic findings) to 39 (maximal myasthenic deficits) obtained by summing the responses to each individual item (None=0, Mild=1, Moderate=2, Severe=3). | Baseline, 12 months, 24 months, 36 months, 48 months | |
Primary | Change in MG-specific Activities of Daily Living scale (MG-ADL). | The MG-ADL is an 8-item scale to assess symptoms of myasthenia gravis patients obtained by summing the responses to each individual item (Grades: 0,1,2,3). The score ranges from 0 to 24. | Baseline,3months, 6 months, 9 months, 12 months, 18 months, 24 months, 30months, 36 months, 42 months, 48 months | |
Primary | The proportion of patients reaching minimal manifestations (MM) or better. | Clinical statuses of patients are assessed and categorized according to Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS). MM or better includes Minimal Manifestation (MM), Pharmacologic Remission (PR) or Complete Remission (CR). | 48 months | |
Secondary | Proportion of Patients with Treatment-related Adverse Experiences. | Treatment-Related Adverse Events (AEs) are evaluated in patients of different regimens. | 3 months, 6 months, 12 months, 24 months, 36 months, 48 months | |
Secondary | Changes in titers of MG antibodies. | MG antibodies are detected at enrollment and the titers of antibodies will be monitored annually. | Baseline, 12 months, 24 months, 36 months, 48 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05039190 -
Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients
|
Phase 3 | |
Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
Completed |
NCT01727193 -
The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy
|
Phase 3 | |
Completed |
NCT00285350 -
Mycophenolate Mofetil in Myasthenia Gravis
|
Phase 3 | |
Recruiting |
NCT05890833 -
The Risk of Falls Index for Patients With Neuromuscular Disorders
|
||
Completed |
NCT05694234 -
Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study
|
||
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Not yet recruiting |
NCT04965987 -
Oxaloacetate in Myasthenia Gravis
|
Phase 1 | |
Not yet recruiting |
NCT05095103 -
Immune Profiles in Myasthenia Gravis
|
||
Completed |
NCT02774239 -
A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)
|
Phase 3 | |
Completed |
NCT02066519 -
Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis
|
N/A | |
Terminated |
NCT02102594 -
Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)
|
Phase 2 | |
Completed |
NCT02118805 -
Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
|
||
Terminated |
NCT01828294 -
Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
|
Phase 1 | |
Terminated |
NCT00727194 -
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
|
Phase 2 | |
Completed |
NCT04590716 -
Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
|
||
Recruiting |
NCT04837625 -
Study of Myasthenic Crisis in China
|
||
Not yet recruiting |
NCT01469858 -
Perception and Multisensory Integration in Neurological Patients Using fMRI
|
N/A | |
Completed |
NCT05408702 -
Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
|
||
Completed |
NCT03205306 -
Myasthenia Gravis and Psyche
|